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Abstract
Treatment with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) or escalated(e)-BEACOPP (bleomycin,
etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisolone) remains the international standard of
care for advanced-stage classical Hodgkin lymphoma (HL). We performed a retrospective, multicentre analysis of 221 non-trial
(“real-world”) patients, aged 16–59 years, diagnosed with advanced-stage HL in the Anglia Cancer Network between 2004 and
2014, treated with ABVD or eBEACOPP, and compared outcomes with 1088 patients in the Response-Adjusted Therapy for
Advanced Hodgkin Lymphoma (RATHL) trial, aged 18–59 years, with median follow-up of 87.0 and 69.5 months, respectively.
Real-world ABVD patients (n=177) had highly similar 5-year progression-free survival (PFS) and overall survival (OS) com-
pared with RATHL (PFS 79.2% vs 81.4%; OS 92.9% vs 95.2%), despite interim positron-emission tomography-computed
tomography (PET/CT)-guided dose-escalation being predominantly restricted to trial patients. Real-world eBEACOPP patients
(n=44) had superior PFS (95.5%) compared with real-world ABVD (HR 0.20, p=0.027) and RATHL (HR 0.21, p=0.015), and
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superior OS for higher-risk (international prognostic score ≥3 [IPS 3+]) patients compared with real-world IPS 3+ ABVD (100%
vs 84.5%, p=0.045), but not IPS 3+ RATHL patients. Our data support a PFS, but not OS, advantage for patients with advanced-
stage HL treated with eBEACOPP compared with ABVD and suggest higher-risk patients may benefit disproportionately from
more intensive therapy. However, increased access to effective salvage therapies might minimise any OS benefit from reduced
relapse rates after frontline therapy.
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Introduction
Treatment with ABVD (doxorubicin, bleomycin, vinblastine,
and dacarbazine) or escalated(e)-BEACOPP (bleomycin,
etoposide, doxorubicin, cyclophosphamide, vincristine, pro-
carbazine, and prednisolone) remains the international stan-
dard of care for the management of adult patients with
advanced-stage classical Hodgkin lymphoma (HL). In 2009,
10-year follow-up data from the German Hodgkin Study
Group (GHSG) HD9 trial showed a significant improvement
in both disease control (time-to-treatment-failure) and overall
survival (OS) for patients treated upfront with standard-dose
BEACOPP or eBEACOPP, compared with alternating cycles
of COPP (cyclophosphamide, vincristine, procarbazine, and
prednisone) and ABVD [1]. Subsequently, eBEACOPP was
introduced as a treatment option at six cancer centres in the
Anglia Cancer Network (ACN) for certain patients for whom
it was considered clinically appropriate, whilst two other ACN
centres continued to offer ABVD for all patients. From 2008
to 2012, four of the ACN centres also recruited patients onto
the Response-Adjusted Therapy for Advanced Hodgkin
Lymphoma (RATHL) trial. In RATHL, all patients received
two cycles of ABVD followed by an interim positron-
emission tomography-computed tomography (PET/CT) scan
(iPET2) to guide further treatment intensity. Patients with a
negative iPET2 scan (Deauville score 1–3) were randomised
1:1 to receive a further four cycles of ABVD or AVD (without
bleomycin). Patients with a positive iPET2 scan (Deauville
score 4–5) had their treatment intensified and received either
a further three cycles of eBEACOPP or four cycles of
BEACOPP-14 (standard-dose BEACOPP delivered every
14 days), without randomisation. Radiotherapy (RT) was not
mandated in the trial protocol but could be offered at the
discretion of the treating clinician. The 3-year follow-up re-
sults of RATHL have been published [2].
In our retrospective study, we looked specifically at young
patients, aged 16–59 years, with advanced-stage HL who
were treated with first-line ABVD or eBEACOPP in the
ACN over a 10-year period (2004–2014), which included
the 5 years immediately preceding and following the introduc-
tion of eBEACOPP at six ACN centres in 2009.We compared
our outcomes against an updated 5-year analysis of outcomes
for RATHL patients, aged 18–59 years. This allowed us to
compare progression-free survival (PFS) and OS for patients
treated upfront with ABVD or eBEACOPP in a non-trial (so-
called real-world), multicentre setting, against patients treated
in a large, contemporary ABVD-based prospective trial that
incorporated interim-PET/CT-guided dose-escalation for pa-




We collected data retrospectively from eight cancer centres in
the Anglia Cancer Network (ACN), including Cambridge
University Hospital and Nuffield Hospital, Cambridge;
Norfolk and Norwich University Hospital, Norwich; Ipswich
Hospital, Ipswich; James Paget University Hospital, Great
Yarmouth; Hinchingbrooke Hospital, Hinchingbrooke;
Peterborough City Hospital, Peterborough; Queen Elizabeth
Hospital, King’s Lynn; andWest Suffolk Hospital, Bury Saint
Edmunds. Eligible patients were identified by review of elec-
tronic and paper hospital records, local cancer registry data,
and the NHS database. Study inclusion criteria included all
young (aged 16–59 years), treatment-naïve patients diagnosed
with advanced-stage HL (stage IIB–IV, or IIA with bulk dis-
ease defined as >0.33 transthoracic diameter or >10cm) in the
ACN between July 1, 2004, and June 31, 2014, who were
treated outside of a clinical trial (so-called real-world) with
either upfront ABVD or eBEACOPP. To provide comparable
durations of follow-up, real-world ABVD and eBEACOPP
patients were censored in April 2016 and January 2019, re-
spectively, and RATHL trial patients were censored in
June 2019.
Statistical analysis
Statistical analysis was conducted using Stata version 16.1
software (StataCorp, TX, USA). Baseline variables of interest
were calculated using standard summary statistics and includ-
ed age at diagnosis, sex, biopsy date, Ann Arbor stage, inter-
national prognostic score (IPS), treatment regimen, use of ra-
diotherapy, date of relapse and/or death. Pearson’s chi-
squared test for categorical variables was applied for the com-
parison between groups. Survival analysis was calculated
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from the date of diagnostic biopsy to the date of first progres-
sion or death from all causes. Surviving patients without pro-
gression were censored at the date they were last known to be
alive. Survival estimates with 95% confidence intervals were
calculated using the Kaplan-Meier method and compared
using the log-rank test. Hazard ratios (HR) with 95% confi-
dence intervals were calculated using a Cox regression model.
A p-value of <0.05 was considered significant. Median
follow-up duration was calculated using the reverse Kaplan-
Meier method, and was censored at death from all causes.
Statistical analysis of the 5-year follow-up data from the
RATHL trial for patients aged 18–59 years, and subsequent
comparative analysis with our real-world ACN cohort, was
performed by the RATHL trial team.
Results
We identified 250 patients, aged 16–59 years, diagnosed with
advanced-stage HL in the ACN from July 1, 2004, to June 31,
2014. This number is in keeping with the expected incidence
for the ACN population of 2.64 million [3]. Of these 250
patients, 29 were excluded, including 25 who were treated in
the RATHL trial, three who were treated with regimens other
than ABVD or eBEACOPP, and one who died before com-
mencing therapy. There were 221 patients eligible for study
inclusion, with a median follow-up of 87 months. A flowchart
of the treatment pathway for the whole cohort is shown in Fig.
1. Real-world patient outcomes were compared with 5-year
outcomes for patients treated in the RATHL trial, aged 18–59
years (n=1088), with a median follow-up of 69.5 months.
Comparison of the baseline characteristics of real-world
and RATHL patients showed highly similar age and sex dis-
tribution, but the real-world cohort had significantly fewer
stage II patients and significantly more stage IV (p < 0.001)
and higher risk (IPS 3+) patients (p = <0.001), compared with
the RATHL trial (Table 1). In the real-world cohort, there was
a patient–clinician bias to treat higher-risk patients with more-
intensive induction therapy, with 75% of eBEACOPP patients
being IPS 3+ compared with only 39% of ABVD patients
(p<0.001)
The 5-year PFS and OS estimates for the whole cohort of
real-world patients (n=221) were 82.5% and 93.9%, respec-
tively. These results were highly similar for RATHL patients
aged 18–59 years (n=1088); PFS 81.4%; HR 1.05, p = 0.79;
OS 95.2%, p=0.71; Fig. 2 Of the 177 real-world ABVD pa-
tients, the majority (n=130; 73.4%) completed six cycles of
ABVD, and 41 (23.2%) completed eight cycles. Interim-PET/
CT scans were not routinely performed in the real-world set-
ting. Five patients (2.8%) had their treatment intensified to
eBEACOPP after two, three, or four cycles of ABVD, and
two patients (1.1%) were de-escalated to ChlVPP
(chlorambucil, vinblastine, procarbazine, and prednisolone)
after three cycles of ABVD. Bleomycin was stopped after
two or three cycles in 15 patients (8.5%) because of pulmo-
nary toxicity. Twenty patients of the ABVD cohort (11%)
received consolidative radiotherapy (RT) after completing
frontline chemotherapy, including 16/20 who were treated
exclusively with ABVD therapy (15/16 received RT to areas
of residual bulk and 1/16 for progressive disease), 3/20 who
had their treatment intensified to eBEACOPP (3/3 received
IFRT to areas of residual bulk), and 1/20 who had their treat-
ment de-escalated to ChlVPP). By comparison, 154 (14%)
RATHL patients had their treatment intensified to
eBEACOPP or BEACOPP-14 after two cycles of ABVD as
per trial protocol, and 73 (6.7%) patients received
consolidative RT [2].
Of the 44 real-world eBEACOPP patients, 31 (70.5%)
were treated exclusively with eBEACOPP, of which the
Fig. 1 Flowchart of the treatment pathway for 221 young advanced-stage
classical Hodgkin lymphoma patients diagnosed in the Anglia Cancer
Network, from 2004 to 2014. ABVD, doxorubicin, vinblastine,
bleomycin, and dacarbazine; BEACOPP, bleomycin, etoposide,
doxorubicin, cyclophosphamide, vincristine, procarbazine, and
prednisolone; ChlVPP, chlorambucil, vinblastine, procarbazine, and
prednisolone; eBEACOPP, escalated-BEACOPP
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majority (n=25; 80.6%) completed six cycles, four (12.9%)
completed five cycles, one (3.2%) completed seven cycles,
and one (3.2%) completed eight cycles. Six patients (13.6%)
were de-escalated to standard-dose BEACOPP after either
two (n=3, 6.8%), three (n=1, 2.3%), or four (n=2, 4.5%) cy-
cles of eBEACOPP. Seven patients (15.9%) were de-
escalated to ABVD after one (n=1, 2.3%), two (n=4, 9.1%),
three (n=1, 2.3%), or four (n=1, 2.3%) cycles of eBEACOPP.
De-escalation was primarily required because of toxicity;
however, three patients requested de-escalation due to fertility
concerns. Of the 44 eBEACOPP patients, 5 patients (11%)
received consolidative RT to areas of residual nodal tissue >
2cm with residual metabolic uptake on PET/CT. No patients
in this cohort had RT for primary refractory disease. Kaplan-
Meier curves of PFS and OS for real-world patients, by treat-
ment regimen, and RATHL trial patients are shown in Fig. 3.
The 5-year PFS and OS estimates for real-world ABVD
patients (n=177) were 79.2% and 92.9% respectively.
Survival outcomes were highly similar in RATHL patients,
aged 18–59 years; PFS 81.4%, HR 1.05, p=0.79; OS 95.2%,
p=0.71. Although the real-world eBEACOPP cohort com-
prised proportionately more higher-risk patients (75% were
IPS 3+, compared with 39% of real-world ABVD patients
and 33% of RATHL patients), it had a statistically signifi-
cant PFS advantage compared with the real-world ABVD
cohort (HR 0.20, p=0.027) and RATHL trial (HR 0.21,
p=0.015; Fig. 3a). However, there was no statistically sig-
nificant OS advantage (Fig. 3b).
Table 1 Baseline characteristics
of 221 young advanced-stage
Hodgkin lymphoma patients
treated in the real-world (RW)
setting compared with 1088








adapted therapy for advanced
Hodgkin lymphoma
Baseline characteristics Real-world, N=221 RATHL, N=1088
Median age at diagnosis—y (range) 35 (16–59) 31 (18–59)
Male sex—n (%) 121 (54.8) 585 (53.8)
Median follow-up—mo. (95% CI)
Whole cohort 87.0 (83.0–94.0) 69.5 (67.2–69.5)
ABVD 87.0 (83.0–94.3) –
eBEACOPP 88.0 (79.3–102.1) –
Ann Arbor stage—n (%)
II with adverse features 62 (28.1) 471 (43.3)
III 68 (30.8) 312 (28.7)
IV 91 (41.2) 305 (28.0)
International Prognostic Score—n (%)
0–2 117 (52.9) 728 (67.0)
3–6 102 (46.2) 359 (33.0)
Unknown 2 (0.9) 1 (0.0)
Initial treatment—n (%)
ABVD 177 (80.1) 1088 (100.0)
eBEACOPP 44 (19.9) 0 (0.0)
†
Fig. 2 Kaplan-Meier curves of survival estimates for the whole cohort of
real-world (RW) patients compared with RATHL trial patients. a
Progression-free survival (PFS). b Overall survival (OS). HR, hazard
ratio; RATHL, response-adapted therapy for advanced Hodgkin
lymphoma; †log rank p-value; *fails the assumption of proportional
hazards
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With the RATHL trial, a higher IPS was associated with a
poorer response to ABVD induction therapy, with 22.1% of
IPS 3+ patients being iPET2-positive versus 12.9% of IPS 0–2
patients. With ongoing follow-up, IPS remains prognostic of
5-year PFS (HR 1.61, p=0.0008) despite a greater proportion
of IPS 3+ patients receiving treatment intensification (Fig. 4a).
Real-world IPS 3+ eBEACOPP patients had signifi-
cantly improved 5-year PFS and OS estimates compared
with real-world IPS 3+ ABVD patients (PFS 97.0% vs
71.9%; HR 0.09, p=0.021, Fig. 4b; OS 100% vs 84.5%,
p=0.0449, Fig. 4c). In addition, real-world IPS 3+
eBEACOPP patients retained a significant PFS benefit
compared with IPS 3+ RATHL patients (97.0% vs
76.3%; HR 0.10, p=0.005; Fig. 4b) despite 22.1% of
IPS 3+ RATHL patients receiving treatment intensifica-
tion after two cycles of ABVD, as per protocol. Although
a higher OS rate was observed for the real-world IPS 3+
eBEACOPP patients compared to the IPS 3+ RATHL
patients (100% vs 91.4%; HR 0.27), this did not reach
statistical significance (p=0.16) (Fig. 4c).
The 5-year survival estimates for real-world and RATHL
trial patients are presented for all patient subgroups in Table 2.
Fertility
Seventeen pre-menopausal women were treated with up-
front eBEACOPP in our real-world cohort, of which 13
(76.5%) were younger than 30 years at diagnosis.
Following completion of treatment, 12 (70.6%) regained
menstrual periods (11 of whom were younger than 30
years at diagnosis), four (23.5%) were diagnosed with
premature ovarian failure, and one (5.9%) died from com-
plications related to allogeneic stem cell transplantation.
At the time of data collection, five of these 17 women
(29.4%) had had a total of seven pregnancies, which re-
sulted in five live-births and two terminations of
pregnancy.
Use of stem cell transplantation
Figure 5 shows a flowchart of real-world patients treated
with stem cell transplantation (SCT) for relapsed/
refractory HL or second malignancies, after frontline ther-
apy with ABVD or eBEACOPP. There was a statistically
significant difference in the rate of autologous SCT
(autograf t ) be tween the rea l -wor ld ABVD and
eBEACOPP groups (p=0.0415). In the real-world ABVD
cohort, 26 patients (14.7%) received an autograft; in 25
patients, this was after salvage therapy for relapsed HL,
and in one patient as treatment of T-cell lymphoma. Three
real-world ABVD patients (1.7%) had an allogeneic SCT
(allograft) for relapsed HL, including one patient who had
previously had an autograft.
In the real-world eBEACOPP group, one patient
(2.3%) had an autograft after salvage therapy for re-
lapsed HL, followed by an allograft after a second re-
lapse. A further two eBEACOPP patients had an allo-
graft, both without previous autograft, including one pa-
tient with relapsed HL who did not mobilise sufficient
stem cells for an autograft after salvage chemotherapy
and who received an allograft after a second relapse,
and one patient with therapy-related myelodysplastic
syndrome (t-MDS), comprising a total of three
eBEACOPP patients (6.8%) who received an allograft
compared with 1.7% in the ABVD group.
Fig. 3 Kaplan-Meier curves of survival estimates for real-world (RW)
patients, grouped by treatment regimen, compared with RATHL trial
patients. a Progression-free survival (PFS). b Overall survival (OS).
ABVD, doxorubicin, vinblastine, bleomycin, and dacarbazine;
eBEACOPP, escalated-bleomycin, etoposide, doxorubicin,
cyclophosphamide, vincristine, procarbazine, and prednisolone; HR,
hazard ratio; RATHL, response-adapted therapy for advanced Hodgkin
lymphoma; †log rank p-value; *fails the assumption of proportional
hazards
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Discussion
ABVD and eBEACOPP remain the most widely used first-
line treatments of advanced-stage HL, and are recommended
treatment options in both the current UK and European
Society for Medical Oncology (ESMO) guidelines [4, 5]. It
is broadly accepted that eBEACOPP offers more effective
anti-Hodgkin therapy, but at the cost of additional toxicity.
As such, it remains a case-by-case decision as to which regi-
men is more appropriate for a given patient.
In this retrospective study, we compared the outcomes of
patients treated with upfront ABVD or eBEACOPP in a
multicentre real-world setting, against patients treated in the
RATHL trial. A strength of this study is the multi-hospital
real-world dataset that has been rigorously checked to include
all age-appropriate patients treated for Hodgkin lymphoma in
the cancer network over a 10-year period. However, there are
inherent limitations with real-world retrospective case studies
which include treatment selection bias and particularly with
our study, the relatively small number of patients and events in
the eBEACOPP treatment cohort which inevitably introduces
more uncertainty in the subsequent comparative statistical
analysis. The over-representation of stage II patients in
RATHL compared with other large prospective Hodgkin lym-
phoma trials has been the subject of previous discussion [6],
but despite this limitation, it is the largest contemporary
multicentre trial evaluating ABVD in the modern era. A sim-
ilar but smaller trial was run by the US SWOG group (S0816)
where iPET-positive patients were also intensified to
eBEACOPP. In contrast with RATHL, however, only stage
III/IV patients were included and dose-intensified patients re-
ceived 6 rather than 4 cycles of eBEACOPP. The overall 5-
year PFS for S0816 was 74% which appears inferior to
RATHL, possibly reflecting the inclusion criteria for the trial.
Fig. 4 Kaplan-Meier curves of survival estimates for real-world (RW)
and RATHL trial patients, grouped by treatment regimen and
international prognostic score (IPS). a Progression-free survival (PFS)
for RATHL trial patients, grouped by IPS. b PFS for IPS 3+ real-world
patients, grouped by treatment regimen, compared with IPS 3+ RATHL
trial patients. c Overall survival (OS) for IPS 3+ real-world patients,
grouped by treatment regimen, compared with IPS 3+ RATHL trial
patients. ABVD, doxorubicin, vinblastine, bleomycin, and dacarbazine;
eBEACOPP, escalated-bleomycin, etoposide, doxorubicin,
cyclophosphamide, vincristine, procarbazine, and prednisolone; HR,
hazard ratio; RATHL, response-adapted therapy for advanced Hodgkin
lymphoma; † log rank p-value; *fails the assumption of proportional
hazards
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Both RATHL and SWOG S0816 reflect the modern practice
of using minimal consolidative RT and we felt RATHL was
an appropriate benchmark for comparison with our real-world
dataset. The PFS curves of the real-world ABVD patients and
RATHL trial patients, aged younger than 60 years, are re-
markably similar in both the absolute 5-year estimates of
progression-free survival and in the kinetics of relapse. This
is observed in both the whole ABVD cohort and IPS 3+ sub-
group, and is consistent with data published from the
Netherlands that suggest similar outcomes are achieved for
HL patients who are treated within or outside of clinical trials
[7].
It is clear from RATHL that higher-risk (IPS 3+) patients
are more likely to be iPET2 positive after ABVD induction
therapy, and despite treatment intensification with
eBEACOPP or BEACOPP-14, they also had a higher relapse
rate (32.5%) at 3 years [2]. Whilst, intuitively, it seems appro-
priate to intensify therapy in iPET2-positive patients, this has
not been tested in a randomised trial and the magnitude of
benefit from this strategy is unknown. Notably, only 2.6%
Table 2 Summary of 5-year survival estimates for real-world (RW) and
RATHL trial patients, grouped by treatment regimen, clinical stage, and
international prognostic score (IPS). ABVD, doxorubicin, vinblastine,
bleomycin, and dacarbazine; eBEACOPP, escalated-bleomycin,
etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine,
and prednisolone; HR, hazard ratio; RATHL, response-adapted therapy
for advanced Hodgkin lymphoma; *fails the assumption of proportional
hazards
Endpoint/group RW ABVD
5-year rate % (n; 95% CI)
RW eBEACOPP
5-year rate % (n; 95% CI)
RATHL
5-year rate % (n; 95% CI)
RW ABVD vs RATHL
HR (95% CI); p-value
Progression-free survival
Whole cohort 79.2 (177; 72.3–84.5) 95.5 (44; 83.0–98.8) 81.4 (1088; 78.9–83.7) 1.05 (0.73–1.50); 0.79
IPS 0–2 84.7 (106; 76.2–90.3) 90.9 (11; 50.8–98.7) 84.1 (728; 81.1–86.6) 0.89 (0.52–1.50); 0.66
IPS 3+ 71.9 (69; 59.5–81.1) 97.0 (33; 80.4–99.6) 76.3 (359; 71.3–80.5) 1.14* (0.69–1.88); 0.60
Stage IV 73.6 (59; 60.0–83.2) 96.9 (32; 79.8–99.6) 77.0 (305; 71.6–81.5) 1.04 (0.59–1.82); 0.90
Overall survival
Whole cohort 92.9 (177; 87.8–95.9) 97.7 (44; 84.9–99.7) 95.2 (1088; 93.7–96.4) 1.12* (0.61–2.05); 0.71
IPS 0–2 98.1 (106; 92.5–99.5) 90.9 (11; 50.8–98.7) 96.7 (728; 95.0–97.9) 0.47 (0.14–1.59); 0.22
IPS 3+ 84.5 (69; 72.9–91.4) 100 (33; N/A) 92.2 (359; 88.7–94.7) 1.62 (0.80–3.31); 0.18
Stage IV 92.6 (59; 81.3–97.2) 100 (32; N/A) 91.5 (305; 87.4–94.3) 0.82 (0.31–2.16); 0.69
Fig. 5 Flowchart of real-world patients treated with autologous
(autograft) and/or allogeneic (allograft) stem cell transplantation for
relapsed/refractory classical Hodgkin lymphoma (HL) or second
malignancies, grouped by initial treatment regimen. ABVD,
doxorubicin, vinblastine, bleomycin, and dacarbazine; eBEACOPP,
escalated-bleomycin, etoposide, doxorubicin, cyclophosphamide,
vincristine, procarbazine, and prednisolone; NHL, non-Hodgkin
lymphoma; t-MDS, therapy-related myelodysplastic syndrome
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of real-world ABVD patients had treatment intensification to
eBEACOPP after induction ABVD, compared with 16.1% of
RATHL patients, yet there was no observed difference in PFS
between the real-world ABVD and RATHL patients in either
the whole ABVD cohort or IPS 3+ subgroup. This suggests
that either the magnitude of benefit for treatment intensifica-
tion based on an iPET2 scan is limited or that there are un-
known competing factors influencing the data.
In both our study and clinical trials, it seems that higher-
risk patients achieve the greatest relative gain in PFS when
treated with upfront eBEACOPP compared with ABVD. The
RATHL trial has shown that even with interim-PET/CT-di-
rected treatment intensification, IPS 3+ patients have an infe-
rior PFS compared with IPS 0–2 patients. This is not solely
explained by fewer patients achieving an iPET2-negative re-
mission, as those IPS 3+ patients who achieved an iPET2-
negative remission had a higher risk of relapse compared with
IPS 0–2 patients (18.3% vs 13.1% at 3 years, HR 1.44 [1.04–
2.01], p=0.029) [2] (Kirkwood, A, personal communication,
2016).
Although there has never been a randomised prospective
trial that compared six cycles of eBEACOPP with six cycles
of ABVD, randomised trials that have compared variations of
these regimens have consistently shown a first-remission PFS
advantage with upfront eBEACOPP, ranging from 5 to 18%
[8–10]. The 5-year PFS difference between patients treated
with upfront eBEACOPP compared with ABVD in our unse-
lected real-world cohort was 16%. In keeping with prospec-
tive trial data, OS estimates were excellent in both of our
treatment groups, suggesting that patients who relapse are
frequently salvaged, albeit with the need for more toxic regi-
mens. The comparative infrequency of relapse in real-world
eBEACOPP patients correlates with their significantly lower
likelihood of receiving an autologous stem cell transplant,
compared with ABVD patients. Although not planned pro-
spectively, there was clear clinician bias to treat IPS 3+ pa-
tients with upfront eBEACOPP in those centres where it was
available. Notably, IPS 3+ eBEACOPP patients were also
observed to have a disproportionate PFS benefit compared
with IPS 3+ ABVD patients.
With regard to OS, IPS 3+ real-world eBEACOPP patients
had an OS advantage compared with IPS 3+ real-world
ABVD patients and showed a difference of just over 8% in
5-year OS when compared with IPS 3+ RATHL patients.
Although this did not reach statistical significance, this may
be due to the small number of patients and events, particularly
within the real-world cohort (1 event in 33 patients). This
difference is not that dissimilar to differences shown in
meta-analyses comparing upfront ABVD to BEACOPP [11]
which saw 5-year OS differences of 7% between ABVD (88%
5-year OS) and 6 cycles of eBEACOPP (95%).
As treatments for first line and relapsed Hodgkin lympho-
ma evolve and more options become available for our
patients, the number of younger adults dying from Hodgkin
lymphoma is thankfully decreasing. However, all treatment
options at relapse bring more toxicities for patients, particu-
larly when transplant strategies are employed, and achieving a
durable first remission remains a highly important goal for our
patients. With the publication of the HD18 and AHL2011
trials [12, 13], the cumulative toxicity of eBEACOPP strate-
gies has been reduced with no impact on PFS, making the
eBEACOPP strategy even more appealing as a first-line treat-
ment option for advanced stage HL. Indeed, with longer
follow-up of HD18, patients who achieved an interim meta-
bolic remission after 2 cycles of eBEACOPP had an improved
overall survival when treated with a total of 4 cycles of
eBEACOPP compared with 6–8 cycles, owing to a reduction
in treatment-related mortality [14]. This confirms that PET-
guided strategies can optimise the PFS and OS for the major-
ity of eBEACOPP-treated patients, whilst reducing the overall
toxicity of the regimen.
Reduced fertility is a significant concern for patients treated
with eBEACOPP. We reviewed the outcomes for menstrual
cycle recovery and fertility after eBEACOPP and found con-
sistent premature ovarian failure in pre-menopausal women
aged over 30 years at diagnosis (n=4), with only one patient
having a transient return of menstrual periods. Of the 13 pre-
menopausal women treated with eBEACOPP aged under 30
years at diagnosis, the majority (n=11, 84.6%) regained men-
strual periods and several pregnancies have been carried to
term. Using anti-mullerian hormone levels as a surrogate for
fertility, prospective follow-up of female patients from the
RATHL study has confirmed that age over 35 and treatment
with BEACOPP were both independent predictors of reduced
AMH levels post-treatment, whilst the majority of woman
under 35 treated with ABVD/AVD regained pre-treatment
AMH levels by 2 years post-treatment [15]. Reducing the
number of cycles of eBEACOPP is likely to help preserve
fertility. Prospective trials that use interim-PET/CT assess-
ment to de-escalate the better-risk patients after eBEACOPP
induction therapy, such as in the recently published LYSA
AHL2011, and HD18 trials, have shown encouraging results
[12, 16]. It is now general practice in the UK to offer pre-
treatment fertility counselling, including potential oocyte stor-
age, to all women of reproductive age when clinically
appropriate.
Second primary malignancies (SPM) are another concern
for patients receiving first-line therapy for Hodgkin lympho-
ma and relative risks remain elevated for patients compared
with age-matched controls whether treated with chemotherapy
alone or in combination with radiotherapy. Meta-analysis of
large trial datasets suggests an increased risk of therapy-
related acute myeloid leukemia/myelodysplastic syndromes
in patients treated with dose-intensified therapy [12].
However, as seen with our real-world dataset, patients treated
with ABVD are more likely to need dose intensification after
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an interim PET scan or at relapse, so it remains difficult to
advise patients of their individual long-term risk of a SPM
when first-line therapy choices are made. With the RATHL
patients to date, 4 non-cutaneous SPMs have been diagnosed
in 154 patients who were dose escalated to BEACOPP-based
chemotherapy (Kirkwood, A; personal communication).
In conclusion, our data provide further evidence that the
outcomes for frontline treatment of young adults (aged youn-
ger than 60 years) with advanced-stage HL in a real-world
setting are highly similar to those achieved in prospective
clinical trials. Although RATHL-style intensification of ther-
apy for iPET2-positive patients has become an accepted stan-
dard of care in the UK, 5-year PFS estimates for RATHL
patients, aged 18–59 years, were highly similar to patients
treated in a multicentre real-world setting with no iPET2-
guided intensification strategy. We observed a clear PFS ben-
efit for patients treated with upfront eBEACOPP and recent
UK data have shown that since the publication of HD18, there
has been a marked increase in the number of UK centres using
eBEACOPP/eBEACOPDacarbazine as first-line therapy to
treat advanced stage HL [17].
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